Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Zai Lab Limited

Market Cap 1.98B 1.71B 1.58B 1.48B 2.77B 188B 2.81B 18.63B 7.26B 91.69B 7.44B 7.28B 317B P/E Ratio 2026 *
-7.97x
P/E Ratio 2027 * -9.46x
Enterprise Value 1.54B 1.33B 1.22B 1.15B 2.15B 146B 2.18B 14.46B 5.64B 71.19B 5.78B 5.65B 247B EV / Sales 2026 *
3.43x
EV / Sales 2027 * 2.68x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 week+0.67%
Current month-1.96%
1 month-10.71%
3 months-9.64%
6 months-1.96%
Current year+0.67%
1 week 13.7
Extreme 13.7
15.2
1 month 13.7
Extreme 13.7
18
3 years 12.8
Extreme 12.8
38.8
5 years 12.8
Extreme 12.8
150
Manager TitleAgeSince
Chief Executive Officer 60 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 60 01/04/2014
Director/Board Member 82 01/01/2017
Director/Board Member 74 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
-1.33%+0.67%-58.10%-41.86% 1.98B
+0.11%-3.67%+17.30%-18.82% 62.21B
+1.44%+5.93%+66.81%+220.92% 59.45B
+0.70%+29.50%+29.50%+29.50% 38.9B
+0.26%+16.11%-55.36%-64.79% 36.4B
+0.05%+2.41%+51.20%-36.17% 29.52B
+0.65%+6.01%+56.79%+74.77% 21.54B
+0.54%+5.21%+82.49%-59.59% 19.7B
+4.80%+0.07%-4.38%+103.05% 16.18B
+0.18%-1.39%+44.85%+98.37% 15.89B
Average +1.15%+2.37%+23.11%+30.54% 33.31B
Weighted average by Cap. +0.94%+2.94%+30.04%+43.97%

Financials

2026 *2027 *
Net sales 449M 388M 357M 334M 626M 42.65B 636M 4.22B 1.64B 20.76B 1.68B 1.65B 71.88B 596M 514M 474M 444M 832M 56.61B 844M 5.6B 2.18B 27.55B 2.24B 2.19B 95.41B
Net income -241M -208M -192M -179M -336M -22.9B -342M -2.26B -883M -11.15B -904M -885M -38.59B -156M -135M -125M -117M -218M -14.87B -222M -1.47B -573M -7.24B -587M -575M -25.07B
Net Debt -443M -383M -353M -330M -619M -42.12B -628M -4.16B -1.62B -20.5B -1.66B -1.63B -70.99B -387M -334M -308M -288M -541M -36.8B -549M -3.64B -1.42B -17.91B -1.45B -1.42B -62.02B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
12/06/26 14.80 -1.33%
11/06/26 15.00 -0.66%
10/06/26 15.10 +6.34%
09/06/26 14.20 -0.70%
08/06/26 14.30 -1.38%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
17.64USD
Average target price
33.30USD
Spread / Average Target
+88.79%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!